Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies
112 - 117
BRIT J CANCER
MetadataShow full item record
AuthorsMorris, JK; George, LM; Wu, T; Wald, NJ
Showing items related by title, author, creator and subject.
Reply to Pontus Eriksson, Gottfrid Sjodahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed Protein Expression to Predict Outcome to Targeted Therapy in Bladder Cancer: Too Little, Too Late? Powles, T; de Liano, AG; Ackerman, C (2017-11)
Are international differences in breast cancer survival between Australia and the UK present amongst both screen-detected women and non-screen-detected women? Survival estimates for women diagnosed in West Midlands and New South Wales 1997–2006 Woods LM, Rachet B, O'Connell DL, et al (London School of Hygiene and Tropical Medicine, UK; Cancer Council NSW, Australia; et al) Int J Cancer 138:2404-2414, 2016§ Laake, JP (2016-01-01)
Benefits and harms of breast cancer mammography screening for women at average risk of breast cancer: A systematic review for the European Commission Initiative on Breast Cancer. Canelo-Aybar, C; Ferreira, DS; Ballesteros, M; Posso, M; Montero, N; Solà, I; Saz-Parkinson, Z; Lerda, D; Rossi, PG; Duffy, SW (Sage, 2021-02-25)OBJECTIVES: Mammography screening is generally accepted in women aged 50-69, but the balance between benefits and harms remains controversial in other age groups. This study systematically reviews these effects to inform ...